Amgen price target lowered to $333 from $340 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Amgen (AMGN) to $333 from $340 and keeps an Equal Weight rating on the shares. Biotech could benefit from broader market leadership…
Fiscal Year: January - December
Amgen Inc. (AMGN), listed on the NASDAQ, has a market capitalization of $196.12B. As of Jul 11, 2026, the stock is trading at $363.39 per share@else an unavailable price , offering investors a clear view of its current market value. Amgen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 25.29, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Amgen Inc. also offers a dividend yield of 2.77%, making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Amgen Inc. (AMGN). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for Amgen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Amgen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Amgen Inc. is 22.81, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Amgen Inc. (AMGN) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Amgen Inc. (AMGN) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Amgen Inc. (AMGN) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Amgen Inc.. To access the full SS Score, consider upgrading your subscription.
Amgen Inc. is a significant player in the industry sector, with a market capitalization of $196.12B and a competitive P/E ratio of 25.29. Investors should compare these metrics with industry peers to gauge whether Amgen Inc. is outperforming or underperforming within its sector.
Morgan Stanley lowered the firm’s price target on Amgen (AMGN) to $333 from $340 and keeps an Equal Weight rating on the shares. Biotech could benefit from broader market leadership…
Truist raised the firm’s price target on Amgen (AMGN) to $340 from $327 and keeps a Hold rating on the shares as part of a broader research note previewing Q2…
A federal judge on Wednesday blocked Colorado from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U.S. state.
The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen's rare-disease drug, citing concerns that patient outcome data were alt...
A clinical trial, originally published in 2021, which was used to approve Amgen’s (AMGN) Tavneos was retracted Monday from the New England Journal of Medicine at the request of two…
The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.
The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, Tavneos, citing a lack of benefits that outweigh its risks.
According to a letter from the U.S. FDA, ChemoCentryx personnel “manipulated” study data to make Tavneos, a pill made to treat a rare blood vessel disorder, appear more effective, Ike…
Mizuho analyst Salim Syed raised the firm’s price target on Amgen (AMGN) to $303 from $295 and keeps a Neutral rating on the shares. The firm updated the company’s model…
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaw...
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it seeks to prove its benefits following the U.S. health regulator's proposal to withdraw it from t...
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $340 from $332 and keeps an Equal Weight rating on the shares. The firm, which says…
Amgen (AMGN) announced new data at the American Diabetes Association, ADA, 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditio...
VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes New Real-World Data Highlight Treatment Gaps in Current Ob...
Goldman Sachs lowered the firm’s price target on Amgen (AMGN) to $389 from $425 and keeps a Buy rating on the shares. The firm is adjusting its model as the…
THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m.
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile wit...
Amgen (AMGN) announced that the European Commission has granted marketing authorization for Imdylltra as a monotherapy to treat adults with extensive-stage small cell lung cancer who require systemic ...
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.